A Drug-Eluting Balloon Improves Outcomes for Coronary Bifurcation Lesions: Results from the BEYOND Trial

Coronary bifurcation lesions—where one coronary artery splits into two branches—are among the trickiest cases in interventional cardiology. They make up 15–20% of all procedures, and while “simple” strategies (like stenting only the main branch) are preferred to avoid complications, they often leave the smaller “side branch” at risk of narrowing or closing off. Now, a landmark Chinese trial suggests a new tool—paclitaxel-eluting balloons (PEBs)—could solve this problem by protecting side branches without extra stents.

The Challenge of Coronary Bifurcation Lesions

When a coronary artery splits (into a “main branch” and “side branch”), plaque buildup can block blood flow to both. For years, doctors used complex double-stent strategies to treat both branches—but these often led to higher rates of heart attack or stent blood clots. The shift to “simple” single-stent strategies (stenting only the main branch) reduced complications but created a new issue: the side branch could narrow (ostium stenosis) or close entirely after the main branch stent was placed.

Enter drug-eluting balloons (DEBs). Unlike stents, which stay in the artery permanently, DEBs are temporary: a balloon coated with a drug (like paclitaxel) is inflated in the narrowed vessel. The drug is absorbed into the artery wall, stopping the overgrowth of cells that cause restenosis (re-narrowing). For bifurcation lesions, DEBs offer a way to treat the side branch without adding a second stent.

What Is the BEYOND Trial?

The BEYOND trial—a prospective, multicenter randomized study—tested whether a paclitaxel-eluting balloon (Bingo®, made by Yinyi Biotech, China) was safer and more effective than a regular uncoated balloon for side branches in non-left main coronary bifurcation lesions. It’s one of the largest studies to date on DEBs for this use, enrolling 222 patients across 10 Chinese hospitals between 2014 and 2015.

How the Trial Worked

Patients with new (de novo) bifurcation lesions were randomly assigned to two groups:

PEB Group: After stenting the main branch, doctors used a paclitaxel-eluting balloon to dilate the side branch.
Regular Balloon Group: The side branch was dilated with a standard uncoated balloon.

All patients followed a “provisional T-stenting” strategy—meaning the main branch got a drug-eluting stent (DES), and the side branch was only treated with a balloon (no extra stent unless there was an emergency like a closed artery). The primary goal was to measure target lesion stenosis (TLS)—how much the side branch narrowed—at 9 months using detailed X-ray analysis (quantitative coronary angiography, QCA). Secondary goals included safety outcomes like heart attack, stroke, or need for repeat procedures.

Key Results: PEB Beats Regular Balloon for Angiographic Outcomes

At 9 months, the PEB group showed significantly better results than the regular balloon group:

Target Lesion Stenosis: The PEB group had 28.7% narrowing vs. 40.0% in the regular balloon group—a 11.3% reduction (95% confidence interval: -16.3% to -6.3%, P < 0.0001). This means the side branch stayed wider in the PEB group.
Late Lumen Loss: A measure of how much the artery re-narrowed over time. The PEB group had less loss (-0.06 mm vs. 0.18 mm in the regular balloon group, P < 0.0001). In simple terms: the PEB kept the side branch open better long-term.

Safety Was Similar

Crucially, the PEB group didn’t have more complications. At 9 months:

No deaths, heart attacks (non-fatal), or stent blood clots in either group.
Major Adverse Cardiac and Cerebral Events (MACCEs): Only 0.9% in the PEB group vs. 3.7% in the regular balloon group (not a statistically significant difference). These events were mostly strokes, not related to the procedure itself.
No patients needed repeat procedures (target lesion revascularization) in either group.

Why This Matters

Previous studies on DEBs for bifurcation lesions were small or single-center. The BEYOND trial—with 222 patients—provides stronger evidence that PEBs are a viable option for side branches. Here’s what stands out:

Better Angiographic Outcomes: The PEB’s ability to deliver paclitaxel directly to the side branch reduced restenosis more effectively than a regular balloon. Paclitaxel stops early cell overgrowth, which is key to preventing re-narrowing.
Safe and Easy to Use: The PEB had the same success rate as regular balloons for crossing and dilating lesions. No extra complications meant doctors could use it confidently.
Ideal for Small Vessels: Over a third of patients had side branches smaller than 2 mm—a group where stents are risky. The PEB worked well here, offering a “stent-free” option for tiny vessels.

Real-World Example: A Patient’s Success Story

One patient in the trial had a severe narrowing in the first diagonal branch (a side branch off the left anterior descending artery). After using the PEB, the artery looked clear immediately post-procedure. At 9 months, there was no sign of restenosis—the side branch stayed open, and the patient had no symptoms. This is exactly what doctors hope for: a long-lasting solution without extra hardware.

Limitations to Consider

While the results are promising, the trial has a few caveats:

Short Follow-Up: 9 months is enough to measure early restenosis, but we don’t know how the PEB performs over 2–5 years. Longer follow-up will show if the benefits last.
Angiographic vs. Clinical Outcomes: The PEB improved X-ray results (like TLS), but clinical outcomes (e.g., fewer heart attacks) were similar to the regular balloon group. More time is needed to see if better angiographic results translate to fewer real-world problems.

What This Means for Patients and Doctors

For patients with coronary bifurcation lesions: The PEB offers a safer, more effective way to protect the side branch without adding a second stent. This is especially good news for people with small vessels or diabetes (31% of trial patients had diabetes), who are at higher risk of restenosis.

For doctors: The BEYOND trial supports using PEBs in side branches after main branch stenting. The German Consensus Group recommends DEBs for bifurcation lesions, and this trial adds Chinese data to back that up.

Conclusion

The BEYOND trial is a big step forward for treating coronary bifurcation lesions. The paclitaxel-eluting balloon (PEB) was significantly better than a regular balloon at keeping the side branch open at 9 months—with no extra safety risks. While we need longer follow-up to confirm long-term benefits, this study suggests DEBs could become a standard tool for protecting side branches in bifurcation procedures.

For more details, read the original study published in the Chinese Medical Journal:
Jing QM, et al. A drug-eluting Balloon for the trEatment of coronarY bifurcatiON lesions in the side branch: a prospective multicenter ranDomized (BEYOND) clinical trial in China. Chin Med J 2020;133(8):899–908.
doi.org/10.1097/CM9.0000000000000743

Trial registered at ClinicalTrials.gov (NCT02325817).

Was this helpful?

0 / 0